Eli Lilly has stopped development of semagacestat, a gamma secretase inhibitor for the treatment of Alzheimer’s disease, as it has not shown favourable results in long-term Phase III studies.
The two Phase III trials involved 2,600 patients with mild-to-moderate Alzheimer’s disease, who received either semagacestat or a placebo.
Go deeper with GlobalData
The drug did not slow down the progression of the disease, and patients taking it showed worsening cognition and ability to perform daily activities.
Semagacestat was also associated with increased risk of skin cancer.
Lilly is instructing the clinical trial investigators to contact and inform the study patients to immediately stop taking semagacestat.
Lilly has announced that the decision to halt the drug development does not affect the ongoing trials of solanezumab, its other potential Alzheimer’s treatment.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
